

ISSUER INFORMATION AND DISCLOSURE STATEMENT

PURSUANT TO

RULE 15C2-11

February 15, 2005

**HEE CORPORATION, INC.
6209 N K61 HIGHWAY
HUTCHINSON, KS 67205**

INFORMATION AND DISCLOSURE STATEMENT

FEBRUARY 15, 2005

ALL INFORMATION FURNISHED HEREIN HAS BEEN PREPARED FROM BOOKS AND RECORDS OBTAINED FROM THE COMPANY IN ACCORDANCE WITH RULE 15c2-11(a)(5) PROMULGATED UNDER THE SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, AND IS INTENDED ONLY AS INFORMATION TO BE USED BY SECURITIES BROKER-DEALERS.

NO DEALER, SALEMAN OR ANY OTHER PERSON HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATIONS NOT CONTAINED HEREIN OR IN CONNECTION WITH THE COMPANY. ANY REPRESENTATIONS NOT CONTAINED HEREIN MUST NOT BE RELIED UPON AS HAVING BEEN MADE OR AUTHORIZED BY THE COMPANY.

The undersigned hereby certifies that the information herein is true and correct to the best of his knowledge and belief.

Date: February 15, 2005

HEE CORPORATION, INC.

By: s/s Radley Brooks
President

COPIES OF THIS INFORMATION AND DISCLOSURE STATEMENT ARE AVAILABLE FROM THE ISSUER UPON REQUEST.

HEE CORPORATION, INC.

INFORMATION AND DISCLOSURE STATEMENT

February 15, 2005

ITEM 1: The exact name of the issuer and its predecessor (if any).

HEE Corporation, Inc. formerly The Goldberg Report, Ltd (hereinafter referred to as the “Company” or “HEE”).

In answering this item, please also provide any names used by predecessor entities in the past five years.

ITEM 2: The address of its principal executive offices.

**6209 North K61 Highway
Hutchinson, KS 67502
Phone: (620) 663-3333
Fax: (620) 663-3358
www.HEE-CORP.com**

Web site for HEE Corporation, Inc.

www.HEE-CORP.com

Investor Relations Contact for the Issuer:

**Darci Brooks
HEE Corporation, Inc.
6209 North K61 Highway
Hutchinson, KS 67502
Phone: (620) 663-3333
Fax: (620) 663-3358
darci@hee-corp.com**

In answering this item, please also provide (i) the telephone and fax number of the issuer’s principal executive offices, (ii) if applicable, the URL of each web site maintained by or on behalf of the issuer, and (iii) if applicable, the name, phone number, email address, and mailing address of the person responsible for the issuer’s investor relations.

ITEM 3: The state and date of incorporation, if it is a corporation.

Please provide the issuer’s state of incorporation (if the issuer is a corporation) or

state of organization (if the issuer is not a corporation) and the date on which it was incorporated or organized.

HEE Corporation, Inc. (formerly The Goldberg Report, Ltd) was incorporated in the State of Delaware on December 11, 2003.

ITEM 4: The exact title and class of each class of securities outstanding.

**Security Symbol: HCCF
CUSIP Number: 42279X 10 3
Common Stock - \$0.000001**

**Security Symbol: HCCFP
CUSIP Number: - 42279X 20 2
Preferred Stock - \$0.000001**

In addition, please provide the CUSIP and trading symbol. In answering this item, provide the requested information for each class of securities outstanding.

ITEM 5: The par or stated value of the security.

Two Hundred Million (200,000,000) shares of common stock was authorized to be issued in the Articles of Incorporation filed on December 11, 2003. The Company increased this to Five Hundred Million (500,000,000), par value \$0.000001 shares of common stock authorized by Board Resolution on November 12, 2004.

The Company, by Board Resolution, increased the authorized shares from Five Hundred Million (500,000,000) shares of common stock par value \$0.000001, to One Billion (1,000,000,000) shares of common stock with a par value of \$0.000001 on January 12, 2005.

Fifty Million (50,000,000), par value \$0.000001 shares of preferred stock authorized in the Articles of Incorporation on December 11, 2003

On August 25, 2004 the Board of Directors voted to declare a stock dividend to its common shareholders of record on September 6, 2004 of one new preferred share of HEE Corporation, Inc. for each common share held. The number of preferred shares, par value \$0.000001, authorized and outstanding is Seventy-Nine Million Three Hundred Forty-Eight Thousand Three Hundred and Eighty-Five (79,348,385).

In answering this item, provide the requested information for each class of securities outstanding.

ITEM 6: The number of shares or total amount of the securities outstanding

for each class of securities outstanding and a list of securities offerings in the past two years.

A. The number of Shares Outstanding year ended December 31, 2004.

- i. HCCF was originally authorized by the Articles of Incorporation of the company to issue Two Hundred Million (200,000,000) shares of common stock and Fifty Million (50,000,000), shares of preferred stock, both with a par value of \$0.00001.

On August 25, 2004 the Board of Directors adopted a Resolution declaring a stock dividend to its common shareholders of one non-transferable preferred share for each common share held on September 6, 2004.

On November 12, 2004 the Board of Directors adopted a Resolution increasing the authorized number of common shares from Two Hundred Million (200,000,000) to Five Hundred Million (500,000,000). On January 12, 2005 the Board of Directors adopted a Resolution increasing the authorized number of common shares from Five Hundred Million (500,000,000) to One Billion (1,000,000,000).

- ii. There are currently Six Hundred Four Million Six Hundred Eighty-Five Thousand and Seventy-Three (604,685,073) common shares issued and outstanding and Seventy-nine Million Three Hundred Forty-Eight Thousand Three Hundred and eighty-five (79,348,385) preferred shares issued and outstanding.

iii. Six Hundred Four Million Six Hundred Eighty-Five Thousand and seventy-three (604,685,073) shares of the common stock in HCCF are issued and designated as free trading. Thirty Million (30,000,000) shares of the Six Hundred Four Million Six Hundred Eighty-Five Thousand and Seventy-Three (604,685,073) of common stock in HCCF are issued and restricted from trading until December 2, 2005. There are currently Seventy-Nine Million Three Hundred Forty-Eight Thousand Three Hundred and Eighty-Five (79,348,385) preferred shares outstanding.

- iv. As of November 6, 2004 there were 2,288 common

shareholders of record in HCCF.

On January 26, 2005 First Public Securities Transfer Corporation advised the Company via e-mail they were resigning as the Stock Transfer Agent effective immediately. The Company has yet to receive a listing of the shareholders of common and preferred stock as of December 31, 2004.

On February 11, 2005 the Company entered into an agreement with a new Stock Transfer Agent. The Company's new Stock Transfer Agent is:

Michael Ajzenman
Madison Stock Transfer
P. O. Box 145
Brooklyn, New York 11229-0145
Phone: (718) 627-4453
Fax: (718) 627-6341
msti@verizon.net

Madison Stock Transfer is presently in the process of auditing the shareholder list for the common and preferred shares of the company. No irregularities are anticipated or expected to be found although the exact number of shareholders of each class of stock has not yet been fully determined.

v. The Company completed a 504 offering in the State of Texas pursuant to the Securities Act of 1933, Regulation D, rule 504 promulgated thereunder by the Commission. The offering, consisting of One Million Five Hundred Thousand (1,500,000) shares of common stock of the company for \$15,000.00 along with those securities issued pursuant to the offering, were registered with the State of Texas on April 28, 2004.

vi. The Company completed a 504 offering in the State of Texas pursuant to the Securities Act of 1933, Regulation D, rule 504 promulgated thereunder by the Commission. The offering, along with those securities issued pursuant to the offering, were registered with the State of Texas on May 7, 2004 and consisted of One Hundred Fifty-Five Thousand (155,000) shares of common stock of the Company; and May 26, 2004 and consisted of Sixty-Nine Thousand Seven Hundred Fifty (69,750) shares of common stock of the Company; and June 3, 2004 and consisted of Three Hundred Fifty-Seven Thousand One Hundred Forty-Three (357,143) shares of the

common stock of the Company with an aggregated value of \$54,837.50.

vii. The Company completed a 504 offering in the States of Texas and Colorado pursuant to the Securities Act of 1933, Regulation D, rule 504 promulgated thereunder by the Commission. The offering, consisted of Four Hundred Fifty-Five Thousand (455,000) shares of the common stock of the Company for \$25,000.00 along with those securities issued pursuant to the offering were registered with the State of Texas on June 7, 2004.

ITEM 7: The name and address of the transfer agent.

The Issuer's Stock Transfer Agent during 2004 was:

**David Corwin
First Public Securities Transfer Corporation
4546 B-10 El Camino Real #288
Los Altos, CA 94022
Phone: (310) 770-6689
Fax: (310) 861-5311
adman@firstpublicsecurities.com**

The address in Canada for the Stock Transfer Agent is:

**David Corwin
First Public Securities Transfer Corporation
3266 Yonge Street
Suite 1203
Toronto, Ontario M4N3P6**

The transfer agent is registered under the Exchange Act and is regulated by the Securities and Exchange Commission.

On February 11, 2005 the Company entered into an agreement with a new Stock Transfer Agent due to the sudden and unexpected resignation of First Public Securities Transfer Corporation on January 26, 2005. The Company's new Stock Transfer Agent is:

**Michael Ajzenman
Madison Stock Transfer
P. O. Box 145
Brooklyn, New York 11229-0145
Phone: (718) 627-4453**

Fax: (718) 627-6341
msti@verizon.net

The new transfer agent is registered under the Exchange Act and is regulated by the Securities and Exchange Commission.

In answering this item, please also provide the telephone number of the transfer agent, indicate whether or not the transfer agent is registered under the Exchange Act, and state the appropriate regulatory authority of the transfer agent. If the security is not listed on an exchange, Pink Sheets requires the transfer agent to be registered under the Exchange Act in order for a broker to quote the security on the Pink Sheets on an unsolicited basis.

ITEM 8: The nature of the issuer's business.

In describing the issuer's business, please provide the following information:

A. Business Development. Describe the development of the issuer and material events during the last three years so a potential investor can clearly understand the history and development of the business. If the issuer has not been in business for three years, provide this information for any predecessor company. This business development description should also specifically include:

1. the form of organization of the issuer (e.g., corporation, partnership, limited liability company, etc.);

HCCF was incorporated under General Corporate Law of the State of Delaware on December 11, 2003 under the name of HEE Corporation, Inc.

2. the year that the issuer (or any predecessor) was organized;

HEE Corporation, Inc. was organized by the filing of Articles of Incorporation with the State of Delaware on December 11, 2003. The predecessor company, The Goldberg Report, Ltd, was organized on September 19, 2002 as a Canadian Company.

3. the issuer's fiscal year end date;

The fiscal year end date for the company is December 31.

4. whether the issuer (and/or any predecessor) has been in bankruptcy, receivership or any similar proceeding;

The predecessor company and HEE Corporation, Inc. has not and is not in the process of filing bankruptcy, receivership or any similar proceeding.

5. any material reclassification, merger, consolidation, or purchase or sale of a significant amount of assets not in the ordinary course of business;

The Company has not made any material reclassifications, mergers, consolidations, or purchases or sales of any significant amount of assets.

6. any default of the terms of any note, loan, lease, or other indebtedness or financing arrangement requiring the issuer to make payments;

No.

7. any change of control;

No. HEE Corporation, Inc. has not had any change of control but will notify Pinksheets if any changes occur.

HEE Corporation, Inc. does state that Sandy Winick resigned as President of HEE Corporation, Inc. on December 1, 2004. On December 8, 2004, Radley Brooks was named as the President/CEO of HEE Corporation, Inc. to serve in an interim capacity until a new Chairman or President was selected.

On January 19, 2005, Herbert L. Becker was named as Interim Chairman/CEO of HEE Corporation, Inc.

8. any increase in 10% or more of the same class of outstanding equity securities;

On August 25, 2004 the company's Board of Directors declared a stock dividend of one preferred share for each common share held on September 6, 2004.

On November 12, 2004 the company increased the number of authorized shares of common stock from 200,000,000 to 500,000,000. There was no change in the number of authorized preferred shares.

On January 12, 2005 the company increased the number of authorized shares of common stock from 500,000,000

to 1,000,000,000.

9. describe any past, pending or anticipated stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization;

On August 25, 2004 the company's Board of Directors declared a stock dividend of one preferred share for each common share held on September 6, 2004.

On November 12, 2004 the company increased the number of authorized shares of common stock from 200,000,000 to 500,000,000.

On January 12, 2005 the company authorized an increase in the number of shares of common stock from 500,000,000 to 1,000,000,000.

10. any delisting of the issuer's securities by any securities exchange or NASDAQ; and

The company's securities have not been de-listed and are not in the process of being de-listed by the Securities and Exchange Commission or NASDAQ.

11. any current, past, pending or threatened legal proceedings or administrative actions either by or against the issuer that could have a material effect on the issuer's business, financial condition, or operations. State the names of the principal parties, the nature and current status of the matters, and the amounts involved.

No, there are no current, past, pending, or threatening legal proceedings or administrative actions.

B. Business of Issuer. Describe the issuer's business so a potential investor can clearly understand it. Please also include, to the extent material to an understanding of the issuer, the following specific items:

1. the issuer's primary and secondary SIC Codes;

The Primary SIC Code for the company is 5090 and the secondary SIC Code is 8071.

2. if the issuer has never conducted operations, is in the development stage or is currently conducting operations;

The company is currently in the developmental stage.

3. state the names of any parent, subsidiary, or affiliate of the issuer, and describe its business purpose, its method of operation, its ownership, and whether it is included in the financial statements attached to this disclosure document;

Not applicable.

4. the effect of existing or probable governmental regulations on the business;

The company's primary interest in health care products subjects it to an ever changing body of law, rules, regulations, and supervision. Most notable is the current product HPB-84, a nutraceutical, which is subject to review of the Food and Drug Administration (FDA) and all marketing materials are further subject to the review, rules, and regulations of the Federal Trade Commission (FTC). The Company has retained the services of Buchanan Ingersoll, P.C., a law firm well experienced in representing clients who manufacture, distribute and import herbal supplements and nutraceuticals. Buchanan Ingersoll PC is one of the 120 largest law firms in the nation, and has 340 attorneys practicing in its offices throughout the United States. Their attorneys have experience in a range of industries such as pharmaceutical and biomedical, technology, financial institutions, construction, security alarm, franchise and real estate. Within these and other industries, their attorneys focus on more than 65 different practice areas including corporate finance, litigation, tax, government relations and health care. The firm serves national and international clients that include Fortune 500 corporations, start-ups, technology companies and financial institutions. The law firm advises and informs the company as to any pending or proposed legislation or laws that might effect the ability of the company to market and distribute its product(s).

HEE Corporation, Inc. can not use the word "treatment" in any of its marketing or promotional materials. Structure/function claims are not subject to FDA (Food & Drug Administration) review and approval but they are subject to FTC (Federal Trade Commission) enforcement.

If a dietary supplement or nutraceutical makes such a claim, it must state in a disclaimer that the FDA has not evaluated the claim, and that the dietary supplement is not intended to “diagnose, treat, cure or prevent any disease,” because only a drug can legally make such a claim.

Before the Company can make a “Qualified Health Claim” it must first have obtained “Significant Scientific Agreement” and petition the FDA for approval of the qualified health claim. In simple terms, we are unable to submit such a petition until we have completed at least one double-blinded placebo controlled study. That study, at a major university in a south central state, is awaiting IRB approval before it can commence. The Company is prohibited from disclosing the name of the University or Chief Investigator due to an Agreed Confidentiality and Non-Disclosure Agreement.

As a matter of information, since 1993, the FDA has approved a total of only 12 health claims. (Calcium and osteoporosis; Dietary fat and cancer; Sodium and hypertension; Dietary saturated fat and cholesterol and risk of coronary heart disease; Fiber-containing grain products, fruits, and vegetables, and cancer; Fruits, vegetables, and grain products that contain fiber, particularly soluble fiber, and risk of coronary heart disease; Fruits and vegetables and cancer; Folate and neural tube defects; Dietary noncariogenic carbohydrates sweeteners and dental caries; Soluble fiber from certain foods and risk of coronary heart disease; Soy protein and risk of coronary heart disease; and Plant/stenol/stanol esters and risk of coronary heart disease.)

Essentially, all of these QHCs (Qualified Health Claims) contain qualifiers such as “may reduce..., do not promote tooth decay..., and, most recently in the case of walnuts, ...”[D]iets including walnuts can reduce the risk of heart disease.

Contact information for Buchanan Ingersoll, P.C. is:

Donald Segal
Buchanan Ingersoll, P.C.
1776 K Street N.W.,
Suite 800
Washington, DC 20006-2365
Phone: (202) 452-7959
Fax: (202) 452-6057
siegalde@bipc.com

The FDA has been authorized and empowered by Congress to implement new rules and regulations governing Good Manufacturing Processes. Although the FDA has not yet published or announced the rules and regulations pertaining to Good Manufacturing Processes, the Company, on its own initiative has and does require the manufacturer of HPB-84 to provide the appropriate Seal of Good Manufacturing.

5. an estimate of the amount spent during each of the last two fiscal years on research and development activities, and, if applicable, the extent to which the cost of such activities are borne directly by customers;

The Company has spent a great deal of time, preparation, labor, and money on the research and development of the Company and it can only give an estimate of the amount of time and preparation spent for the Research and Development of the Company. The company estimates the value and cost of Research and Development for Company product(s) to be in excess of \$1,000,000. The cost of Research and Development, together with the cost of acquiring the product(s) of the Company are one of the considerations in establishing the market price of Company product(s). It is expected the cost of Research and Development will ultimately be passed through to potential customers over a period of time, generally five to seven years.

6. costs and effects of compliance with environmental laws (federal, state and local); and

The company is not producing any products that are hazardous to the environment and does not foresee any changes that could adversely affect the environment. All products and services are environmentally friendly.

7. number of total employees and number of full-time employees.

The company currently has a total of five (5) employees, of which five employees of the company are considered full time.

C. Investment Policies. For any investments that the issuer has, provide clear descriptions of the investments, any restrictions or impairments the investments may have and the policies used to value and/or depreciate such assets from a financial and tax

perspective. State whether there are any limitations of the percentage of assets which may be invested in any one investment, or type of instrument, and indicate whether such policy may be changed without a vote of security holders. State whether the issuer's policy is to acquire assets primarily for possible capital gain or primarily for income.

The company plans to fund its efforts and all assets that will possibly be acquired will be used to generate income for the company. The company does not own any property, other than intellectual property, and currently does not plan to invest in any of the following.

On August 30, 2004 the company entered into an agreement to purchase the land, buildings, and assets of the Hertzler Halstead Hospital in Halstead, Kansas. Due to legal, environmental, and related issues, the Company determined on October 28, 2004 that it would not be in the best interest of the company to continue to pursue the purchase of the facility. Accordingly, the Company forfeited an earnest money deposit in the amount of \$100,000.00 as liquidated damages in order to secure a release from the Purchase Agreement.

In October 2004 the company examined and considered an additional Office Building in the Kansas City, Kansas area. After further consideration and deliberation, the Company discontinued the search for additional real estate.

It is the current opinion of Company management that investments in real estate would not be in the best interests of the Company and its capital can be put to better use and purpose.

ITEM 9: The nature of products or services offered.

In responding to this item, please describe the following so that a potential investor can clearly understand the products and services of the issuer:

1. principal products or services, and their markets;

HEE Corporation, Inc. has the exclusive world wide distribution rights, except for the country of India, to a nutraceutical known as HPB-84. An herbal supplement, HPB-84 has been shown to be effective and has demonstrated significant promise when used as part of an overall treatment protocol for Type II Diabetic patients.

Diabetes is the 5th leading cause of death in the US and is growing at alarming proportions. By 2012, diabetes is predicted to be the number one leading cause of death in the U.S. By 2012, diabetes is expected to affect over 33 million people in the US alone at a cost of more than \$200 billion per year.

Currently, diabetics rely on various combinations of medications and dietary restrictions in order to keep their diabetic symptoms in check. However, as the illness progresses, sufferers are often forced to add 2nd and 3rd medications to their treatment regimens and/or resort to painful insulin injections. Furthermore, many medications have undesirable side effects such as weight gain, nausea, and restlessness.

The HEE (Health Excellence through Exploration) Corporation (“HEE Corp”, “HEE”, or “Company”) is a publicly traded company that was founded to provide a promising herbal supplement (nutraceutical) for Type 2 diabetes. HEE has named the product “HPB-84”.

HPB-84 – a combination of natural ingredients known to promote metabolic health – was developed in India where it has received widespread acclaim for its perceived ability to effectively stop diabetes. HPB-84 is presently undergoing several major clinical trials in the US; preliminary results have been extremely promising.

HEE aims to generate as much revenue as possible from the sale of HPB-84 during the product’s window of marketability. Towards this end, the Company has encouraged the planning and development of a nationwide network of Wellness Centers that will distribute HPB-84 to their (Type 2) diabetic and pre-diabetic patients.

There are currently in excess of 18.1 million Type II Diabetics in the United States. Diabetes is today, the 5th leading cause of death in the United States. Current forecasts predict that Diabetes will be the leading cause of death in the United States by 2012.

HEE (Health Excellence through Exploration) Corporation will continue to seek out and bring to market other health care products, devices and services to the domestic and international market place.

2. distribution methods of the products or services;

HEE Corporation, Inc. enters into exclusive agreements with others for the distribution of its products and services to the consumer. It is expected the practice of limiting these agreements to companies whose distribution to the public are subject to medical supervision and control will continue.

3. status of any publicly announced new product or service;

The HPB-84 nutraceutical is currently being tested in clinical trials to determine appropriate dosage based upon gender, body mass index, lifestyle of patients, and associated clinical values. It is expected HPB-84 will be administered to paying patients during the first quarter of 2005.

4. competitive business conditions, the issuer's competitive position in the industry, and methods of competition;

The Company aims to become a market leader in the field of diabetes treatment and metabolic syndrome. HEE seeks to maximize revenues from its HPB-84 diabetes product on the shoulders of a national network of Wellness Centers. At the same time, HEE strives to use the availability of its diabetes targeted nutraceutical as a means to generate widespread demand for the Wellness Centers.

HPB-84 currently drives the Company's business engine, and its distribution must be handled effectively to promote exposure and sales revenues. The HPB-84 product will be sold through several distribution channels.

Wellness Centers: The Company is assisting in the development and opening of branded centers during 2005. These centers will provide HPB-84 products as part of their specialized diabetes treatment programs. HEE will focus on this channel at launch because it facilitates strict quality control and provides medical supervision of the use of HPB-84.

Franchised Wellness Centers: Going forward, HEE will shift focus toward franchised clinics. The franchise approach is better suited for rapid expansion than a company-owned model because it requires less capital on the part of the Company.

Non-clinic Sales: HPB-84 will also be provided at discounted wholesale rates to certified doctors and other distribution outlets approved by HEE as licensees.

5. sources and availability of raw materials and the names of principal suppliers;

Raw materials for the manufacture of HPB-84 are found in India and other areas in middle eastern countries. The limited and available supply of raw materials for the manufacture of HPB-84 actually works to the advantage of the Company. The lead times required for the manufacture of the product are a factor of somewhat limited supplies. These limitations do create an environment where demand and supply can be managed which permits the company to obtain a premium price for its product.

6. dependence on one or a few major customers;

The method of distributing the company's product through controlled distribution networks with broad geographic locations will permit the company to not become dependent upon only a few major customers.

7. patents, trademarks, licenses, franchises, concessions, royalty agreements or labor contracts, including their duration; and

It is likely if not probable that other companies will attempt to imitate HEE's products and/or services as HEE gains market acceptance. Successful attempts could erode market share, depress prices, and potentially soil HEE's name (in cases where consumers mistake HEE for inferior competitors). Accordingly, protecting its intellectual property is a top priority which HEE is pursuing on several fronts.

Secrecy: HEE will maintain as much secrecy about its product formulas and business practices as is permitted by law. Additionally, it will take all possible measures to conceal the sources of its rare ingredients.

Credibility: By the time any direct competitors enter the arena, HEE will have already established a solid footprint bolstered by reviews from prestigious journals

and a network of on-board medical professionals. Furthermore, HEE will have significant control over its distribution channels. HEE plans to use its accumulated credibility as a means to further improve its position against competitors and/or discredit competing products.

Legal: HEE consults with IP-related counsel and is currently in the process of developing a national IP protection strategy. While full Rx patent protection is not a viable short-term goal, HEE plans to use legal means to slow or stop its competitors' advance. In essence, HEE will apply for a myriad of trademarks, process patents, and product patents in numerous jurisdictions for the primary purpose of creating a legal high ground for itself when disputes arise.

8. the need for any government approval of principal products or services. Discuss the status of any requested government approvals.

Pre-market clearance is required for most medical products, devices, procedures, and drugs. Herbal Supplements, Dietary Supplements, and Nutraceuticals do not require pre-market clearance if the products and/or ingredients were marketed in the United States prior to 1994. All of the ingredients in the Company's proprietary product, HPB-84, were marketed prior to 1994 and do not require pre-market clearance from the FDA.

ITEM 10: The nature and extent of the issuer's facilities.

The Company sub-leases a 2,600 square foot Office Building from Hutch Realty, LLC on a triple net basis at the rate of \$10.00 per square foot. The amount of the annual rent is \$26,000.00 and the company is responsible for taxes, insurance, maintenance, utilities, and grounds keeping. The lease is a one-year lease and expires in March 2005. The Company expects to re-new the lease upon expiration. The Office Building is located at 6209 North K61 Highway, Hutchinson, Kansas 67502.

The Company owns no other real estate nor does it have any plans to acquire any.

ITEM 11: The name of the chief executive officer, members of the board of directors, as well as counsel, accountant and public relations consultant.

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders. In responding to this item, please provide the full names, business addresses, employment histories (which should list all previous employers for the past 10 years, positions held, responsibilities and employment dates), board memberships, other affiliations, and number of securities (and of which class) beneficially owned by each such person, which information must be no older than the end of the most recent fiscal year, for the issuer's:

The company recognizes the importance of having experienced management and top advisors on board. HEE Corp is in the process of establishing an independent Board of Directors and Advisors, which will comprise top experts from scientific, academic and private industry fields. They will provide important guidance and independent advice for the successful operation of the Company's business activities. Upon the successful testing of its HPB-84 product, the Company expects to add a top diabetes expert to serve on its Board.

a. Executive Officers;

The following list sets forth the name, address and position of each executive officer and director of the Issuer as of the date hereof.

<u>Name</u>	<u>Position</u>
Herbert L. Becker HEE Corporation, Inc. 6209 N K61 Highway Hutchinson, KS 67502 Phone: (620) 663-3333 Fax: (206) 350-5392	Chairman/CEO
Radley Brooks HEE Corporation, Inc. 6209 N K61 Highway Hutchinson, KS 67502 Phone: (620) 663-3333 Fax: (620) 663-3358	President

Darci Brooks
HEE Corporation, Inc.
6209 N K61 Highway
Hutchinson, KS 67502
Phone: (620) 663-3333
Fax: (620) 663-3358

Debbie George
HEE Corporation, Inc.
6209 N K61 Highway
Hutchinson, KS 67502
Phone: (620) 663-3333
Fax: (620) 663-3358

**Secretary/
Director Investor Relations**

VP Operations

b. Directors;

Herbert L. Becker
HEE Corporation, Inc.
6209 N K61 Highway
Hutchinson, KS 67502
Phone: (620) 663-3333
Fax: (206) 350-5392

Radley Brooks
6209 N K61 Highway
Hutchinson, KS 67502
Phone: (620) 663-3333
Fax: (620) 663-3358

c. General Partners;

N/A

d. Investment Banker

N/A

e. Promoters;

N/A

f. Control Persons;

N/A

g. Counsel;

Richard Benjes/Wayne Clark

h. Accountant or Auditor; and

Currently examining candidates for Accountant and Auditor

i. Public Relations Consultant (s).

N/A

j. Any other advisor (s) that assisted, advised, prepared or provided information with respect to this disclosure documentation.

None

Please also identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None of the officers or control persons have been convicted or named as a defendant in any criminal proceeding.

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the SEC, the CFTC, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities activities.

None of the officers or control person has a finding or

judgment by a court of competent jurisdiction (in a civil action), the SEC, the CFTC, or a state securities regulator of a violation of federal or state securities or commodities law.

The following table sets forth the ownership for each class of equity securities of the Issuer owned beneficially and of record by all directors and officers of the Issuer.

<u>Name and Position</u>	<u>Common Stock Owned</u>	<u>Percentage Owned</u>
Herbert L. Becker, Chairman	750,000	less than 1%
Radley Brooks, President	113,000	less than 1%
Darci Brooks, Secretary	20,000	less than 1%
Debbie George, VP	47,000	less than 1%

To the extent not otherwise disclosed in response to the foregoing, provide a list of the name, address and shareholdings all persons holding more than five percent (5%) of any class of the issuer's equity securities.

The following table sets forth the ownership for each class of equity securities of the Issuer owned beneficially and of record on January 24, 2005 of the name and shareholdings of all persons holding more than five percent (5%) of any class of the issuer's equity securities.

<u>Name</u>	<u>Common Stock Owned</u>	<u>Percentage</u>
Cede & Company P. O. Box 222 Bowling Green Station New York, N.Y. 10274	422,577,233	42.26%
Ronald D. Brooks 7 Lake Terrace Drive Hutchinson, KS 67502	116,525,000	11.66%

<u>Name</u>	<u>Preferred Stock Owned</u>	<u>Percentage</u>
Cede & Company P. O. Box 222 Bowling Green Station	72,448,771	91.31%

New York, N.Y. 10274

To the extent not otherwise disclosed, if any of the above shareholders are corporate shareholders, provide the disclosure requested in this item as to person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

To the extent not otherwise disclosed, describe any relationships existing among and between the issuer's officers, directors and shareholders.

Ronald D. Brooks who owns 11.66% of the common stock of the issuer, is the father of Radley Brooks, President of the Company and the father-in-law of Darci Brooks, Secretary/Director Investor Relations of the Company.

To the extent not otherwise disclosed, describe all relationships and affiliations among and between the shareholders and the issuer, its predecessors, its present and prior officers and directors, and other shareholders.

ITEM 12: The issuer's most recent balance sheet and profit and loss and retained earnings statements.

The issuer should include the below financial statements in the disclosure document or if attached provide a list in the disclosure document describing the attached financial statements, the balance sheet date and the date published. The issuer should provide a summary of the types of information that the Company will provide to security holders in the future and the schedule for providing this information.

The financial statements requested pursuant to this item should be prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP)². For information regarding U.S. GAAP, see <http://cpaclass.com/gaap/gaap-us-01a.htm>. The issuer should provide adequate disclosure of their current financial position which should include for the most recent fiscal year and any interim quarters :

- 1) a balance sheet,
- 2) a statement of income,
- 3) a statement of cash flows and
- 4) a statement of changes in stockholders' equity.

The balance sheet should be of the end of the issuer's (or its predecessor's) most recent fiscal year and the other financial statements (2, 3 and 4) should be for the 12 months preceding the date of such balance sheet.

The issuer should also provide interim financial statements as of the most recent

fiscal quarter, which include a balance sheet as of the end of the most recent fiscal quarter and statements of income, cash flows and changes in shareholder's equity for the interim period up to the date of such balance sheet and the comparable period of the preceding fiscal year.

Information contained in annual financial statements will not be considered current more than 90 days after the end of the issuer's fiscal year immediately following the fiscal year for which such statement are provided, or with respect to quarterly financial statements, more than 45 days after the end of the quarter immediately following the quarter for which such statements are provided.

All such financial statements should either be audited or contain a certification by the chief financial officer of the issuer, or any other person responsible for the preparation of such statements, that such statements, and the notes thereto, present fairly, in all material respects, the financial position of the issuer and the results of its operations and cash flows for the periods presented, in conformity with accounting principles generally accepted in the United States, consistently applied. In the event that the person providing such certification did not prepare all or some of such statements, disclose the names, position and responsibilities of any persons or entities that were engaged to prepare or provide such information.

Financial information for the Issuer for the period ending December 31, 2004 is being forwarded under separate cover as an Exhibit to this Disclosure.

ITEM 13: Similar financial information for such part of the 2 preceding fiscal years as the issuer or its predecessor has been in existence.

N/A

Please refer to the instructions to item (xii) above in responding to this requirement that adequate financial information be made publicly available for the issuers preceding two years.

ITEM 14: Whether any quotation is being submitted or published directly or indirectly on behalf of the issuer, or any director, officer or any person, directly or indirectly the beneficial owner of more than 10 percent of the outstanding units or shares of any equity security of the issuer, or at the request of any promoter for the issuer, and, if so, the name of such person, and the basis for any exemption under the federal securities laws for any sales of such securities on behalf of such person.

To the best of Company's knowledge, information and belief, quotations with respect to the Issuer's common stock are not being submitted or published, directly or indirectly, on behalf of the Issuer

or on behalf of a director, officer, or beneficial owners of more than 10% percent of the common stock that is issued and outstanding.

CERTIFICATION

I, Radley Brooks, hereby certify that I have reviewed the Information and Disclosure statement, Exhibits, and all notes thereto and; I, having full authority to sign on behalf of the company hereby certify that the information is complete and presented fairly, in all material respects.

Dated the 15th day of February, 2005.

Certified by: /s/ Radley Brooks
Radley Brooks, President